Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Cassava Sciences ( (SAVA) ).
Cassava Sciences has submitted an IND application to the FDA for a clinical trial of simufilam targeting TSC-related epilepsy. The FDA has requested additional information to assess risks and support the study, and Cassava plans to address these issues and initiate the trial in the first half of 2026.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Cassava Sciences, Inc. operates in the pharmaceutical industry, focusing on developing innovative drugs for neurological conditions.
Average Trading Volume: 2,754,954
Technical Sentiment Signal: Sell
Current Market Cap: $146.4M
For detailed information about SAVA stock, go to TipRanks’ Stock Analysis page.